Original Research C hronic cough and sputum production are common, but symptoms vary in patients with COPD. 1 They result from goblet cell hyperplasia in both large and small airways, 2-4 and the subsequent mucus hypersecretion worsens airfl ow obstruction and predisposes to bacterial colonization. 5 Mucus overproduction may develop as a consequence of cigarette smoke exposure, 6,7 acute and chronic viral infection, 8 or infl ammatory cell activation of mucin gene transcription 9 and is compounded by diffi culty in clearing secretions because of poor ciliary function, distal airway occlusion, and ineffective cough. 2,9,10 Chronic mucus hypersecretion has been shown in some large epidemiologic studies to be associated with an accelerated lung function decline, increased risk for respiratory infection, 11,12 and higher mortality. [13][14][15] Several studies have demonstrated an increased risk of COPD exacerbation. [16][17][18][19] Goblet cell hyperplasia also has prognostic value as it has been associated with an increased risk of mortality and a lack of improvement in lung function after lung reduction surgery. 20,21 Despite these clinical and pathologic correlates of chronic bronchitis (CB) to various clinical outcomes, the current literature is limited regarding Background: Chronic bronchitis (CB) in patients with COPD is associated with an accelerated lung function decline and an increased risk of respiratory infections. Despite its clinical significance, the chronic bronchitic phenotype in COPD remains poorly defi ned. Methods: We analyzed data from subjects enrolled in the Genetic Epidemiology of COPD (COPDGene) Study. A total of 1,061 subjects with GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage II to IV were divided into two groups: CB (CB 1 ) if subjects noted chronic cough and phlegm production for Ն 3 mo/y for 2 consecutive years, and no CB (CB 2 ) if they did not. Results: There were 290 and 771 subjects in the CB 1 and CB 2 groups, respectively. Despite similar lung function, the CB 1 group was younger (62.8 Ϯ 8.4 vs 64.6 Ϯ 8.4 years, P 5 .002), smoked more (57 Ϯ 30 vs 52 Ϯ 25 pack-years, P 5 .006), and had more current smokers (48% vs 27%, P , .0001). A greater percentage of the CB 1 group reported nasal and ocular symptoms, wheezing, and nocturnal awakenings secondary to cough and dyspnea. History of exacerbations was higher in the CB 1 group (1.21 Ϯ 1.62 vs 0.63 Ϯ 1.12 per patient, P , .027), and more patients in the CB 1 group reported a history of severe exacerbations (26.6% vs 20.0%, P 5 .024). There was no difference in percent emphysema or percent gas trapping, but the CB 1 group had a higher mean percent segmental airway wall area (63.2% Ϯ 2.9% vs 62.6% Ϯ 3.1%, P 5 .013). Conclusions: CB in patients with COPD is associated with worse respiratory symptoms and higher risk of exacerbations. This group may need more directed therapy targeting chronic mucus production and smoking cessation not only to improve symptoms but also to reduce risk, improve quality of life, and impro...